The present invention discloses an improved nanoemulsion comprising a uniformand discrete range of very small particle nano-sized diameters. Thisuniformity results in improved bioavailability of incorporated compounds(i.e., pharmaceuticals or nutraceuticals) as reflected in variouspharmacokinetic parameters including, but not limited to, decreased Tmax,increased Cmax, and increased AUC. The improved method of making these uniformnanoemulsions utilizes microfluidization which differs in both process andmechanics when compared to conventional milling and grinding techniques usedto generate nanoparticulate compositions. Further, the improvement results, inpart, from a novel step of mixing a substantially soluble compound into aheated dispersion medium. This is unlike current nanoparticulate compositionmethods that mix an insoluble compound with an unheated dispersion medium.Further, these nanoemulsions are observed to be bacterial-resistant and stableto extremes in both temperature and pH changes. Consequently, thesenanoemulsions are expected to have a significantly prolonged shelf-life thancurrently available nanoemulsions.
